Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
HeraMED Ltd. ( (AU:HMD) ) has provided an announcement.
HeraMED Limited has appointed Dr. Sharon R. Howell as a Non-Executive Director and Chair of the Advisory Board. Dr. Howell brings over two decades of global experience in healthcare and technology, having previously served as Chief Performance Officer at Centene Corporation. Her appointment is expected to bolster HeraMED’s strategic planning, healthcare technology partnerships, and commercialization efforts in the US and internationally. This move underscores the company’s commitment to scaling its impact in maternal health and expanding its international footprint.
More about HeraMED Ltd.
HeraMED Limited is an innovative medical data and technology company that is leading the digital transformation of maternity care. The company offers a proprietary platform, HeraCARE, which integrates hardware and software to enhance the prenatal and postpartum experience. Their solutions include the clinically validated in-home fetal and maternal heart rate monitor, HeraBEAT, and utilize cloud computing, artificial intelligence, and big data to improve the doctor-patient relationship and maternal health outcomes.
Average Trading Volume: 2,408,216
Technical Sentiment Signal: Buy
Current Market Cap: A$37.48M
For detailed information about HMD stock, go to TipRanks’ Stock Analysis page.